Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 858M 742M 698M 634M 1.19B 81.91B 1.21B 8.17B 3.2B 41.08B 3.22B 3.15B 137B P/E 2026 *
9.3x
P/E 2027 * 7.64x
Enterprise Value 1.16B 1B 945M 859M 1.61B 111B 1.64B 11.06B 4.32B 55.61B 4.36B 4.27B 185B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.33x
Free-Float
47.23%
Yield 2026 *
-
Yield 2027 * -
1 day+3.62%
1 week+5.55%
Current month+4.86%
1 month+8.40%
3 months+14.14%
6 months-26.63%
Current year-21.92%
1 week 19.55
Extreme 19.55
21.07
1 month 18.5
Extreme 18.5
22.64
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
65.92
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
11/08/26 Sell

Director

-7,973 0.0181%
07/08/26 Fiscal year

Chief Financial Officer

18,286 0.0415%
09/07/26 Free

Director

24,532 0.0556%
Change 5-day change 1-year change 3-year change Capi.($)
+3.62%+5.55%-31.40%-61.77% 858M
-2.25%-0.99%+78.68%+123.40% 1,078B
-0.66%+1.31%+49.27%+49.76% 632B
-0.54%+2.29%+23.82%+63.92% 443B
-1.99%-2.63%+42.21%+33.92% 356B
-1.05%-2.19%+25.55%+34.88% 289B
-2.12%-3.29%+0.14%+3.90% 245B
-0.63%+2.56%+43.51%+58.17% 226B
-1.19%+0.37%-9.57%-52.51% 204B
+0.16%+5.73%+15.17%+72.95% 171B
Average -0.23%+1.48%+23.74%+32.66% 364.46B
Weighted average by Cap. -0.18%+1.30%+43.73%+63.32%

Financials

2026 *2027 *
Net sales 748M 647M 608M 553M 1.04B 71.35B 1.06B 7.12B 2.78B 35.79B 2.81B 2.75B 119B 784M 678M 638M 580M 1.09B 74.84B 1.11B 7.46B 2.92B 37.54B 2.94B 2.88B 125B
Net income 99.32M 85.88M 80.75M 73.41M 138M 9.48B 140M 945M 370M 4.75B 373M 365M 15.82B 115M 99.8M 93.84M 85.31M 160M 11.01B 163M 1.1B 430M 5.52B 433M 424M 18.39B
Net Debt 303M 262M 247M 224M 421M 28.95B 429M 2.89B 1.13B 14.52B 1.14B 1.11B 48.34B 184M 159M 150M 136M 255M 17.57B 260M 1.75B 685M 8.81B 691M 676M 29.33B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
14/08/26 $20.91 +3.62% 305,681
13/08/26 $20.18 +1.00% 526,116
12/08/26 $19.98 -2.15% 343,843
11/08/26 $20.42 +0.54% 570,493
10/08/26 $20.31 -2.26% 645,749
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
20.18USD
Average target price
22.00USD
Spread / Average Target
+9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock